株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

閉経後骨粗鬆症:パイプライン製品の分析

Post Menopausal Osteoporosis - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 213136
出版日 ページ情報 英文 73 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
閉経後骨粗鬆症:パイプライン製品の分析 Post Menopausal Osteoporosis - Pipeline Review, H1 2017
出版日: 2017年05月16日 ページ情報: 英文 73 Pages
概要

閉経後骨粗鬆症とは、骨粗鬆症のもっとも一般的な形態であり、閉経後の女性の多くが罹ります。背痛や身長低下、前屈姿勢などの脊椎変形といった症状があります。年齢、性別、家族歴、骨構造、体重などのリスクファクターがあり、ホルモン補充療法(HRT)、ビタミンD類似体の投与などの治療法があります。

当レポートでは、世界における閉経後骨粗鬆症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

イントロダクション

  • 調査範囲

閉経後骨粗鬆症の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別の治療薬
  • 企業で開発中の製品

閉経後骨粗鬆症:治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

閉経後骨粗鬆症の治療薬開発に従事している企業

  • Amgen Inc
  • Enteris BioPharma Inc
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Ligand Pharmaceuticals Inc
  • Lupin Ltd
  • NIBEC
  • Oncobiologics Inc
  • Paras Biopharmaceuticals Finland Oy

薬剤プロファイル

閉経後骨粗鬆症:休止中のプロジェクト

閉経後骨粗鬆症:開発が中止された製品

閉経後骨粗鬆症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9264IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2017, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Preclinical stages are 4, 1 and 6 respectively.

Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Post Menopausal Osteoporosis - Overview
    • Post Menopausal Osteoporosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Post Menopausal Osteoporosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Enteris BioPharma Inc
    • Intas Pharmaceuticals Ltd
    • Ipsen SA
    • Ligand Pharmaceuticals Inc
    • Lupin Ltd
    • NIBEC
    • Oncobiologics Inc
    • Paras Biopharmaceuticals Finland Oy
  • Post Menopausal Osteoporosis - Drug Profiles
    • abaloparatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • calcitonin DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lasofoxifene tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romosozumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Obesity and Post Menopausal Osteoporosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teriparatide biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Post Menopausal Osteoporosis - Dormant Projects
  • Post Menopausal Osteoporosis - Discontinued Products
  • Post Menopausal Osteoporosis - Product Development Milestones
    • Featured News & Press Releases
      • Apr 28, 2017: FDA Approves Radius Healths TYMLOS (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
      • Apr 07, 2017: Osteoporosis drug found safe in long-term trial
      • Apr 03, 2017: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies
      • Apr 01, 2017: Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab)
      • Mar 10, 2017: Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC
      • Feb 01, 2017: Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis
      • Nov 07, 2016: Amgen To Present Data On Denosumab At ACR/ARHP 2016 Annual Meeting
      • Oct 19, 2016: Research Reveals How Novel Osteoporosis Drug Increases Bone Mass
      • Sep 26, 2016: Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab
      • Sep 19, 2016: Radius Presents Abaloparatide Transdermal Patch Development Program at American Society for Bone and Mineral Research 2016 Annual Meeting
      • Sep 18, 2016: Radius Announces Publication of Additional Positive Results from the Phase 3 ACTIVE Trial of Abaloparatide-SC in JBMR
      • Sep 18, 2016: Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis
      • Sep 14, 2016: Amgen to present romosozumab at Investor Call
      • Sep 07, 2016: UCB to present results from Phase 3 FRAME Study at the American Society for Bone and Mineral Research Annual Meeting
      • Aug 16, 2016: JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women With Osteoporosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Post Menopausal Osteoporosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Post Menopausal Osteoporosis - Pipeline by Amgen Inc, H1 2017
  • Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2017
  • Post Menopausal Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
  • Post Menopausal Osteoporosis - Pipeline by Ipsen SA, H1 2017
  • Post Menopausal Osteoporosis - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
  • Post Menopausal Osteoporosis - Pipeline by Lupin Ltd, H1 2017
  • Post Menopausal Osteoporosis - Pipeline by NIBEC, H1 2017
  • Post Menopausal Osteoporosis - Pipeline by Oncobiologics Inc, H1 2017
  • Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017
  • Post Menopausal Osteoporosis - Dormant Projects, H1 2017
  • Post Menopausal Osteoporosis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Post Menopausal Osteoporosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top